Faster and more cost-effective trials support early-stage research in China driving the country's drug discovery engine.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene ...
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...
Synthekine has entered into a clinical trial partnership and supply agreement with MSD to investigate STK-012 in combination with Keytruda and chemotherapy in patients with first-line, PD-L1 negative ...
Jaguar Gene Therapy has completed Cohort I dosing of its first-in-human clinical trial investigating JAG201 for patients with SHANK3 haploinsufficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results